{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:30:05Z","timestamp":1794857405245,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Meningiomas are the most common primary intracranial tumors in adults. They are initially detected with neuroimaging techniques, but definite histological diagnosis requires tumor surgery to collect tumor tissue. Gross total resection is an optimal and final treatment for the majority of patients, followed by radiotherapy in malignant or refractory cases. However, there are a lot of uncertainties about i.a. the need for intervention in incidental cases, estimation of growth kinetics, risk of malignant transformation, or response to radiotherapy. Therefore a new diagnostic approach is needed. It has already been shown that epigenetics plays a crucial role in cancer biology, development, and progression. DNA methylation, the presence of 5-methylcytosine in DNA, is one of the main elements of a broad epigenetic program in a eukaryotic cell, with superior regulatory significance. Therefore, we decided to look at meningioma through changes of 5-methylcytosine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed an analysis of the total amount of 5-methylcytosine in DNA isolated from intracranial meningioma tissues and peripheral blood samples of the same patients. The separation and identification of radioactively labeled nucleotides were performed using thin-layer chromatography.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that the 5-methylcytosine level in DNA from intracranial meningiomas is inversely proportional to the malignancy grade. The higher the tumor WHO grade is, the lower the total DNA methylation. The amount of 5-methylcytosine in tumor tissue and peripheral blood is almost identical.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We conclude that the total DNA methylation can be a useful marker for brain meningioma detection, differentiation, and monitoring. It correlates with tumor WHO grade, and the 5-methylcytosine level in peripheral blood reflects that in tumor tissue. Therefore it\u2019s applicable for liquid biopsy.<\/jats:p><jats:p>Our study creates a scope for further research on epigenetic mechanisms in neurooncology and can lead to the development of new diagnostic methods in clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-020-06982-3","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T14:34:16Z","timestamp":1591194856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Total DNA methylation as a biomarker of DNA damage and tumor malignancy in intracranial meningiomas"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7179-1474","authenticated-orcid":false,"given":"Anna-Maria","family":"Barciszewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"issue":"Suppl 5","key":"6982_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"QT Ostrom","year":"2019","unstructured":"Ostrom QT, Patil N, Gittleman H, Truitt G, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-Oncology. 2019;21(Suppl 5):v1\u2013v100.","journal-title":"Neuro-Oncology"},{"key":"6982_CR2","doi-asserted-by":"publisher","first-page":"101562","DOI":"10.1016\/j.canep.2019.07.001","volume":"62","author":"B Holleczek","year":"2019","unstructured":"Holleczek B, Zampella D, Urbschat S, Sahm F, von Deimling A, Oertel J, et al. Incidence, mortality and outcome of meningiomas: a population-based study from Germany. Cancer Epidemiol. 2019;62:101562.","journal-title":"Cancer Epidemiol"},{"key":"6982_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803\u201320.","journal-title":"Acta Neuropathol"},{"key":"6982_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(06)70625-1","volume":"5","author":"MJ Riemenschneider","year":"2006","unstructured":"Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. Lancet Neurol. 2006;5:1045\u201354.","journal-title":"Lancet Neurol"},{"key":"6982_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fonc.2013.00227","volume":"3","author":"BP Walcott","year":"2013","unstructured":"Walcott BP, Nahed BV, Brastianos PK, Loeffler JS. Radiation treatment for WHO grade II and III Meningiomas. Front Oncol. 2013;3:227.","journal-title":"Front Oncol"},{"key":"6982_CR6","doi-asserted-by":"publisher","DOI":"10.3171\/2018.1.FOCUS17754","volume":"44","author":"S Gupta","year":"2018","unstructured":"Gupta S, Bi WL, Dunn IF. Medical management of meningioma in the era of precision medicine. Neurosurg Focus. 2018;44:E3.","journal-title":"Neurosurg Focus"},{"key":"6982_CR7","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/neuonc\/noz119","volume":"21","author":"C Horbinski","year":"2019","unstructured":"Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, et al. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology. 2019;21:1498\u2013508.","journal-title":"Neuro-Oncology"},{"key":"6982_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/14737175.2018.1429920","volume":"18","author":"C Apra","year":"2018","unstructured":"Apra C, Peyre M, Kalamarides M. Current treatment options for meningioma. Expert Rev Neurother. 2018;18:241\u20139.","journal-title":"Expert Rev Neurother"},{"key":"6982_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/216084a0","volume":"216","author":"KD Zang","year":"1967","unstructured":"Zang KD, Singer H. Chromosomal constitution of meningiomas. Nature. 1967;216:84\u20135.","journal-title":"Nature."},{"key":"6982_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.wneu.2018.08.019","volume":"119","author":"DT Proctor","year":"2018","unstructured":"Proctor DT, Ramachandran S, Lama S, Sutherland GR. Towards molecular classification of meningioma: evolving treatment and diagnostic paradigms. World Neurosurg. 2018;119:366\u201373.","journal-title":"World Neurosurg"},{"key":"6982_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1136\/jnnp-2019-322257","volume":"91","author":"C Mirian","year":"2020","unstructured":"Mirian C, Duun-Henriksen AK, Juratli T, Sahm F, Spiegl-Kreinecker S, Peyre M, et al. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. J Neurol Neurosurg Psychiatry. 2020;91:378\u201387.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6982_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.clineuro.2010.12.007","volume":"113","author":"GA Alexiou","year":"2011","unstructured":"Alexiou GA, Markoula S, Gogou P, Kyritsis AP. Genetic and molecular alterations in meningiomas. Clin Neurol Neurosurg. 2011;113:261\u20137.","journal-title":"Clin Neurol Neurosurg"},{"key":"6982_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3171\/jns.2001.95.4.0601","volume":"95","author":"R Ketter","year":"2001","unstructured":"Ketter R, Henn W, Niedermayer I, Steilen-Gimbel H, K\u00f6nig J, Zang KD, et al. Predictive value of progression-associated chromosomal aberrations for the prognosis of meningiomas: a retrospective study of 198 cases. J Neurosurg. 2001;95:601\u20137.","journal-title":"J Neurosurg"},{"key":"6982_CR14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1158\/1078-0432.CCR-05-1480","volume":"12","author":"AB Espinosa","year":"2006","unstructured":"Espinosa AB, Tabernero MD, Ma\u00edllo A, Sayagu\u00e9s JM, Ciudad J, Merino M, et al. The cytogenetic relationship between primary and recurrent meningiomas points to the need for new treatment strategies in cases at high risk of relapse. Clin Cancer Res. 2006;12:772\u201380.","journal-title":"Clin Cancer Res"},{"key":"6982_CR15","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/ijc.22855","volume":"121","author":"R Ketter","year":"2007","unstructured":"Ketter R, Urbschat S, Henn W, Feiden W, Beerenwinkel N, Lengauer T, et al. Application of oncogenetic trees mixtures as a biostatistical model of the clonal cytogenetic evolution of meningiomas. Int J Cancer. 2007;121:1473\u201380.","journal-title":"Int J Cancer"},{"key":"6982_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/WCO.0000000000000027","volume":"26","author":"ML Suv\u00e0","year":"2013","unstructured":"Suv\u00e0 ML, Louis DN. Next-generation molecular genetics of brain tumours. Curr Opin Neurol. 2013;26:681\u20137.","journal-title":"Curr Opin Neurol"},{"key":"6982_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13072-015-0016-6","volume":"8","author":"A Breiling","year":"2015","unstructured":"Breiling A, Lyko F. Epigenetic regulatory functions of DNA modifications: 5-methylcytosine and beyond. Epigenetics Chromatin. 2015;8:24.","journal-title":"Epigenetics Chromatin"},{"key":"6982_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-biochem-060713-035513","volume":"83","author":"L Shen","year":"2014","unstructured":"Shen L, Song CX, He C, Zhang Y. Mechanism and function of oxidative reversal of DNA and RNA methylation. Annu Rev Biochem. 2014;83:585\u2013614.","journal-title":"Annu Rev Biochem"},{"key":"6982_CR19","doi-asserted-by":"publisher","first-page":"2568635","DOI":"10.1155\/2016\/2568635","volume":"2016","author":"EG Tora\u00f1o","year":"2016","unstructured":"Tora\u00f1o EG, Garc\u00eda MG, Fern\u00e1ndez-Morera JL, Ni\u00f1o-Garc\u00eda P, Fern\u00e1ndez AF. The impact of external factors on the Epigenome: in utero and over lifetime. Biomed Res Int. 2016;2016:2568635.","journal-title":"Biomed Res Int"},{"key":"6982_CR20","doi-asserted-by":"publisher","first-page":"e2253","DOI":"10.1038\/cddis.2016.105","volume":"7","author":"E Panieri","year":"2016","unstructured":"Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis. 2016;7:e2253.","journal-title":"Cell Death Dis"},{"key":"6982_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/1389450116666150113121054","volume":"16","author":"Q Wu","year":"2015","unstructured":"Wu Q, Ni X. ROS-mediated DNA methylation pattern alterations in carcinogenesis. Curr Drug Targets. 2015;16:13\u20139.","journal-title":"Curr Drug Targets"},{"key":"6982_CR22","doi-asserted-by":"publisher","first-page":"e1007362","DOI":"10.1371\/journal.pgen.1007362","volume":"14","author":"A Nebbioso","year":"2018","unstructured":"Nebbioso A, Tambaro FP, Dell\u2019Aversana C, Altucci L. Cancer epigenetics: moving forward. PLoS Genet. 2018;14:e1007362.","journal-title":"PLoS Genet"},{"key":"6982_CR23","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/cr.2011.140","volume":"21","author":"Z Gong","year":"2011","unstructured":"Gong Z, Zhu JK. Active DNA demethylation by oxidation and repair. Cell Res. 2011;21:1649\u201351.","journal-title":"Cell Res"},{"key":"6982_CR24","doi-asserted-by":"publisher","first-page":"E1065","DOI":"10.3390\/cells8091065","volume":"8","author":"AM Barciszewska","year":"2019","unstructured":"Barciszewska AM, Giel-Pietraszuk M, Perrigue PM, Naskr\u0119t-Barciszewska M. Total DNA methylation changes reflect random oxidative DNA damage in gliomas. Cells. 2019;8:E1065.","journal-title":"Cells"},{"key":"6982_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nm.2305","volume":"17","author":"M Rodr\u00edguez-Paredes","year":"2011","unstructured":"Rodr\u00edguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17:330\u20139.","journal-title":"Nat Med"},{"key":"6982_CR26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1750-3639.2009.00340.x","volume":"20","author":"D Barski","year":"2010","unstructured":"Barski D, Wolter M, Reifenberger G, Riemenschneider MJ. Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol. 2010;20:623\u201331.","journal-title":"Brain Pathol"},{"key":"6982_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11060-010-0411-6","volume":"103","author":"JA Kandenwein","year":"2011","unstructured":"Kandenwein JA, Park-Simon TW, Schramm J, Simon M. uPA\/PAI-1 expression and uPA promoter methylation in meningiomas. J Neuro-Oncol. 2011;103:533\u20139.","journal-title":"J Neuro-Oncol"},{"key":"6982_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.trsl.2012.05.007","volume":"160","author":"A Di Vinci","year":"2012","unstructured":"Di Vinci A, Brigati C, Casciano I, Banelli B, Borz\u00ec L, Forlani A, et al. HOXA7, 9, and 10 are methylation targets associated with aggressive behavior in meningiomas. Transl Res. 2012;160:355\u201362.","journal-title":"Transl Res"},{"key":"6982_CR29","doi-asserted-by":"publisher","first-page":"e54114","DOI":"10.1371\/journal.pone.0054114","volume":"8","author":"F Gao","year":"2013","unstructured":"Gao F, Shi L, Russin J, Zeng L, Chang X, He S, et al. DNA methylation in the malignant transformation of meningiomas. PLoS One. 2013;8:e54114.","journal-title":"PLoS One"},{"key":"6982_CR30","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00432-015-1930-5","volume":"141","author":"A Majchrzak-Celi\u0144ska","year":"2015","unstructured":"Majchrzak-Celi\u0144ska A, Paluszczak J, Szalata M, Barciszewska AM, Nowak S, Baer-Dubowska W. DNA methylation analysis of benign and atypical meningiomas: correlation between RUNX3 methylation and WHO grade. J Cancer Res Clin Oncol. 2015;141:1593\u2013601.","journal-title":"J Cancer Res Clin Oncol"},{"key":"6982_CR31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1093\/carcin\/bgr260","volume":"33","author":"Y Kishida","year":"2012","unstructured":"Kishida Y, Natsume A, Kondo Y, Takeuchi I, An B, Okamoto Y, et al. Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis. 2012;33:436\u201341.","journal-title":"Carcinogenesis."},{"key":"6982_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gendis.2018.01.002","volume":"5","author":"Z Jin","year":"2018","unstructured":"Jin Z, Liu Y. DNA methylation in human diseases. Genes Dis. 2018;5:1\u20138.","journal-title":"Genes Dis"},{"key":"6982_CR33","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1158\/1541-7786.196.2.3","volume":"2","author":"R Zukiel","year":"2004","unstructured":"Zukiel R, Nowak S, Barciszewska AM, Gawronska I, Keith G, Barciszewska MZ. A simple epigenetic method for the diagnosis and classification of brain tumors. Mol Cancer Res. 2004;2:196\u2013202.","journal-title":"Mol Cancer Res"},{"key":"6982_CR34","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/neuonc\/nox071","volume":"19","author":"B Brokinkel","year":"2017","unstructured":"Brokinkel B, Hess K, Mawrin C. Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: a systematic review. Neuro-Oncology. 2017;19:1298\u2013307.","journal-title":"Neuro-Oncology"},{"key":"6982_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ng.2526","volume":"45","author":"PK Brastianos","year":"2013","unstructured":"Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45:285\u20139.","journal-title":"Nat Genet"},{"key":"6982_CR36","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339:1077\u201380.","journal-title":"Science"},{"key":"6982_CR37","doi-asserted-by":"publisher","first-page":"14433","DOI":"10.1038\/ncomms14433","volume":"8","author":"AS Harmanc\u0131","year":"2017","unstructured":"Harmanc\u0131 AS, Youngblood MW, Clark VE, Co\u015fkun S, Henegariu O, Duran D, et al. Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun. 2017;8:14433.","journal-title":"Nat Commun"},{"key":"6982_CR38","doi-asserted-by":"publisher","unstructured":"Muskens IS, Wu AH, Porcel J, Cheng I, Le Marchand L, Wiemels JL, et al. Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the multiethnic cohort. Neuro-Oncology. 2019. https:\/\/doi.org\/10.1093\/neuonc\/noz005.","DOI":"10.1093\/neuonc\/noz005"},{"key":"6982_CR39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-010-0386-3","volume":"99","author":"J Wiemels","year":"2010","unstructured":"Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neuro-Oncol. 2010;99:307\u201314.","journal-title":"J Neuro-Oncol"},{"key":"6982_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.mad.2012.01.005","volume":"133","author":"ML Hegde","year":"2012","unstructured":"Hegde ML, Mantha AK, Hazra TK, Bhakat KK, Mitra S, Szczesny B. Oxidative genome damage and its repair: implications in aging and neurodegenerative diseases. Mech Ageing Dev. 2012;133:157\u201368.","journal-title":"Mech Ageing Dev"},{"key":"6982_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.mrfmmm.2010.12.016","volume":"711","author":"TB Kryston","year":"2011","unstructured":"Kryston TB, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res. 2011;711:193\u2013201.","journal-title":"Mutat Res"},{"key":"6982_CR42","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1093\/nar\/gku334","volume":"42","author":"GS Madugundu","year":"2014","unstructured":"Madugundu GS, Cadet J, Wagner JR. Hydroxyl-radical-induced oxidation of 5-methylcytosine in isolated and cellular DNA. Nucleic Acids Res. 2014;42:7450\u201360.","journal-title":"Nucleic Acids Res"},{"key":"6982_CR43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.dnarep.2015.04.013","volume":"32","author":"S Ito","year":"2015","unstructured":"Ito S, Kuraoka I. Epigenetic modifications in DNA could mimic oxidative DNA damage: a double-edged sword. DNA Repair (Amst). 2015;32:52\u20137.","journal-title":"DNA Repair (Amst)"},{"key":"6982_CR44","first-page":"1016","volume":"7","author":"YA Fouad","year":"2017","unstructured":"Fouad YA, Aanei C. Revisiting the hallmarks of cancer. Am J Cancer Res. 2017;7:1016\u201336.","journal-title":"Am J Cancer Res"},{"key":"6982_CR45","first-page":"49","volume":"2","author":"RR Kanherkar","year":"2014","unstructured":"Kanherkar RR, Bhatia-Dey N, Csoka AB. Epigenetics across the human lifespan. Front Cell Dev Biol. 2014;2:49.","journal-title":"Front Cell Dev Biol"},{"key":"6982_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymeth.2014.08.011","volume":"72","author":"TJ Morris","year":"2015","unstructured":"Morris TJ, Beck S. Analysis pipelines and packages for infinium humanmethylation450 beadchip (450k) data. Methods. 2015;72:3\u20138.","journal-title":"Methods"},{"key":"6982_CR47","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017;18:682\u201394.","journal-title":"Lancet Oncol"},{"key":"6982_CR48","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/neuonc\/noz061","volume":"21","author":"F Nassiri","year":"2019","unstructured":"Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, et al. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology. 2019;21:901\u201310.","journal-title":"Neuro-Oncology"},{"key":"6982_CR49","doi-asserted-by":"publisher","first-page":"BSR20180731","DOI":"10.1042\/BSR20180731","volume":"38","author":"AM Barciszewska","year":"2018","unstructured":"Barciszewska AM. Global DNA demethylation as an epigenetic marker of human brain metastases. Biosci Rep. 2018;38:BSR20180731.","journal-title":"Biosci Rep"},{"key":"6982_CR50","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.lfs.2016.02.002","volume":"148","author":"V Rani","year":"2016","unstructured":"Rani V, Deep G, Singh RK, Palle K, Yadav UC. Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. Life Sci. 2016;148:183\u201393.","journal-title":"Life Sci"},{"key":"6982_CR51","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1186\/1471-2407-14-830","volume":"14","author":"N Al-Moghrabi","year":"2014","unstructured":"Al-Moghrabi N, Nofel A, Al-Yousef N, Madkhali S, Bin Amer SM, Alaiya A. The molecular significance of methylated BRCA1 promoter in white blood cells of cancer-free females. BMC Cancer. 2014;14:830.","journal-title":"BMC Cancer"},{"key":"6982_CR52","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/neuonc\/nop041","volume":"12","author":"I Lavon","year":"2010","unstructured":"Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro-Oncology. 2010;12:173\u201380.","journal-title":"Neuro-Oncology"},{"key":"6982_CR53","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1227\/01.NEU.0000340683.19920.E3","volume":"64","author":"T Wakabayashi","year":"2009","unstructured":"Wakabayashi T, Natsume A, Hatano H, Fujii M, Shimato S, Ito M, et al. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. Neurosurgery. 2009;64:455\u201361.","journal-title":"Neurosurgery"},{"key":"6982_CR54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/07357900500449546","volume":"24","author":"KD Weaver","year":"2006","unstructured":"Weaver KD, Grossman SA, Herman JG. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Investig. 2006;24:35\u201340.","journal-title":"Cancer Investig"},{"key":"6982_CR55","doi-asserted-by":"publisher","first-page":"32067","DOI":"10.1038\/srep32067","volume":"6","author":"F Zhi","year":"2016","unstructured":"Zhi F, Shao N, Li B, Xue L, Deng D, Xu Y, et al. A serum 6-miRNA panel as a novel non-invasive biomarker for meningioma. Sci Rep. 2016;6:32067.","journal-title":"Sci Rep"},{"key":"6982_CR56","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.clineuro.2018.05.001","volume":"170","author":"F Mashayekhi","year":"2018","unstructured":"Mashayekhi F, Saberi A, Mashayekhi S. Serum TIMP1 and TIMP2 concentration in patients with different grades of meningioma. Clin Neurol Neurosurg. 2018;170:84\u20137.","journal-title":"Clin Neurol Neurosurg"},{"key":"6982_CR57","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s13353-013-0149-x","volume":"54","author":"A Majchrzak-Celi\u0144ska","year":"2013","unstructured":"Majchrzak-Celi\u0144ska A, Paluszczak J, Kleszcz R, Magiera M, Barciszewska AM, Nowak S, et al. Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. J Appl Genet. 2013;54:335\u201344.","journal-title":"J Appl Genet"},{"key":"6982_CR58","doi-asserted-by":"publisher","first-page":"e92599","DOI":"10.1371\/journal.pone.0092599","volume":"9","author":"AM Barciszewska","year":"2014","unstructured":"Barciszewska AM, Nowak S, Naskr\u0119t-Barciszewska MZ. The degree of global DNA hypomethylation in peripheral blood correlates with that in matched tumor tissues in several neoplasia. PLoS One. 2014;9:e92599.","journal-title":"PLoS One"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06982-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06982-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06982-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T10:07:12Z","timestamp":1666778832000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06982-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6982"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06982-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"assertion":[{"value":"13 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Blood and tissue molecular analysis was approved by the Bioethical Committee of Karol Marcinkowski University of Medical Sciences, Poznan (896\/9; 838\/12). All participants provided informed and written consent to donate their peripheral blood and tumor tissue samples for research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The patients\u2018clinical details presented in the paper do not compromise anonymity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares that she has no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"509"}}